Cassava Sciences, Inc(NASDAQ:SAVA) 
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-b...
Website: https://www.cassavasciences.com/
Founded: 1998
Full Time Employees: 9
CEO: Remi Barbier
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.20
H 1.31
L 1.17
C 1.30
V 1,555,238
10EMA 1.30
20EMA 1.30
60EMA 1.30
120EMA 1.30
250EMA 1.30